286 related articles for article (PubMed ID: 35074907)
21. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
[TBL] [Abstract][Full Text] [Related]
22. IL-17A-producing CD8
Picard FSR; Lutz V; Brichkina A; Neuhaus F; Ruckenbrod T; Hupfer A; Raifer H; Klein M; Bopp T; Pfefferle PI; Savai R; Prinz I; Waisman A; Moos S; Chang HD; Heinrich S; Bartsch DK; Buchholz M; Singh S; Tu M; Klein L; Bauer C; Liefke R; Burchert A; Chung HR; Mayer P; Gress TM; Lauth M; Gaida M; Huber M
Gut; 2023 Aug; 72(8):1510-1522. PubMed ID: 36759154
[TBL] [Abstract][Full Text] [Related]
23. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.
Langston SP; Grossman S; England D; Afroze R; Bence N; Bowman D; Bump N; Chau R; Chuang BC; Claiborne C; Cohen L; Connolly K; Duffey M; Durvasula N; Freeze S; Gallery M; Galvin K; Gaulin J; Gershman R; Greenspan P; Grieves J; Guo J; Gulavita N; Hailu S; He X; Hoar K; Hu Y; Hu Z; Ito M; Kim MS; Lane SW; Lok D; Lublinsky A; Mallender W; McIntyre C; Minissale J; Mizutani H; Mizutani M; Molchinova N; Ono K; Patil A; Qian M; Riceberg J; Shindi V; Sintchak MD; Song K; Soucy T; Wang Y; Xu H; Yang X; Zawadzka A; Zhang J; Pulukuri SM
J Med Chem; 2021 Mar; 64(5):2501-2520. PubMed ID: 33631934
[TBL] [Abstract][Full Text] [Related]
24. Tumor-neuroglia interaction promotes pancreatic cancer metastasis.
Su D; Guo X; Huang L; Ye H; Li Z; Lin L; Chen R; Zhou Q
Theranostics; 2020; 10(11):5029-5047. PubMed ID: 32308766
[No Abstract] [Full Text] [Related]
25. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
26. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
27. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
Canel M; Sławińska AD; Lonergan DW; Kallor AA; Upstill-Goddard R; Davidson C; von Kriegsheim A; Biankin AV; Byron A; Alfaro J; Serrels A
Gut; 2023 Dec; 73(1):131-155. PubMed ID: 36977556
[TBL] [Abstract][Full Text] [Related]
28. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
Carideo Cunniff E; Sato Y; Mai D; Appleman VA; Iwasaki S; Kolev V; Matsuda A; Shi J; Mochizuki M; Yoshikawa M; Huang J; Shen L; Haridas S; Shinde V; Gemski C; Roberts ER; Ghasemi O; Bazzazi H; Menon S; Traore T; Shi P; Thelen TD; Conlon J; Abu-Yousif AO; Arendt C; Shaw MH; Okaniwa M
Cancer Res Commun; 2022 Jun; 2(6):489-502. PubMed ID: 36923556
[TBL] [Abstract][Full Text] [Related]
29. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
30. Downregulated expression of IL‑28RA is involved in the pathogenesis of pancreatic ductal adenocarcinoma.
Liu L; Qi Y; Huang D; Xu Y; Li M; Hong Z; Gu Y; Jia B; Luo X; Zhang S; Zhang S
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195850
[TBL] [Abstract][Full Text] [Related]
31. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
32. Intestinal microbiota modulates pancreatic carcinogenesis through intratumoral natural killer cells.
Yu Q; Newsome RC; Beveridge M; Hernandez MC; Gharaibeh RZ; Jobin C; Thomas RM
Gut Microbes; 2022; 14(1):2112881. PubMed ID: 35980869
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
Adamska A; Domenichini A; Capone E; Damiani V; Akkaya BG; Linton KJ; Di Sebastiano P; Chen X; Keeton AB; Ramirez-Alcantara V; Maxuitenko Y; Piazza GA; De Laurenzi V; Sala G; Falasca M
J Exp Clin Cancer Res; 2019 Aug; 38(1):312. PubMed ID: 31378204
[TBL] [Abstract][Full Text] [Related]
34. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours.
Huang HC; Sung YC; Li CP; Wan D; Chao PH; Tseng YT; Liao BW; Cheng HT; Hsu FF; Huang CC; Chen YT; Liao YH; Hsieh HT; Shih YC; Liu IJ; Wu HC; Lu TT; Wang J; Chen Y
Gut; 2022 Sep; 71(9):1843-1855. PubMed ID: 34921062
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
Arnoletti JP; Reza J; Rosales A; Monreal A; Fanaian N; Whisner S; Srivastava M; Rivera-Otero J; Yu G; Phanstiel Iv O; Altomare DA; Tran Q; Litherland SA
PLoS One; 2022; 17(3):e0265725. PubMed ID: 35316296
[TBL] [Abstract][Full Text] [Related]
36. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE; Baumgartner F; Heider M; Patra U; Holz M; Braune J; Kaiser M; Schäffer I; Bamopoulos SA; Ramberger E; Murgai A; Ng YLD; Demel UM; Laue D; Liebig S; Krüger J; Janz M; Nogai A; Schick M; Mertins P; Müller S; Bassermann F; Krönke J; Keller U; Wirth M
Blood Adv; 2023 Feb; 7(4):469-481. PubMed ID: 35917568
[TBL] [Abstract][Full Text] [Related]
37. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients.
Lim SA; Kim J; Jeon S; Shin MH; Kwon J; Kim TJ; Im K; Han Y; Kwon W; Kim SW; Yee C; Kim SJ; Jang JY; Lee KM
Front Immunol; 2019; 10():496. PubMed ID: 31024520
[TBL] [Abstract][Full Text] [Related]
38. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
39. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
[TBL] [Abstract][Full Text] [Related]
40. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling.
Seshacharyulu P; Halder S; Nimmakayala R; Rachagani S; Chaudhary S; Atri P; Chirravuri-Venkata R; Ouellette MM; Carmicheal J; Gautam SK; Vengoji R; Wang S; Li S; Smith L; Talmon GA; Klute K; Ly Q; Reames BN; Grem JL; Berim L; Padussis JC; Kaur S; Kumar S; Ponnusamy MP; Jain M; Lin C; Batra SK
EBioMedicine; 2022 Jan; 75():103772. PubMed ID: 34971971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
